WO1991002062A3 - C-erbb-2 external domain: gp75 - Google Patents
C-erbb-2 external domain: gp75 Download PDFInfo
- Publication number
- WO1991002062A3 WO1991002062A3 PCT/US1990/004340 US9004340W WO9102062A3 WO 1991002062 A3 WO1991002062 A3 WO 1991002062A3 US 9004340 W US9004340 W US 9004340W WO 9102062 A3 WO9102062 A3 WO 9102062A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- erbb
- polypeptides
- disclosed
- proteins
- useful
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000003149 assay kit Methods 0.000 abstract 1
- 239000013060 biological fluid Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT90914094T ATE207958T1 (en) | 1989-08-04 | 1990-08-02 | EXTERNAL DOMAIN OF C-ERBB-2:GP75 |
DK90914094T DK0444181T3 (en) | 1989-08-04 | 1990-08-02 | C-erbB-2 External Domain: gp75 |
CA002042064A CA2042064C (en) | 1989-08-04 | 1990-08-02 | C-erbb-2 external domain:gp75 |
DE69033842T DE69033842T2 (en) | 1989-08-04 | 1990-08-02 | OUTSIDE DOMAIN OF C-ERBB-2: GP75 |
EP90914094A EP0444181B2 (en) | 1989-08-04 | 1990-08-02 | C-erbb-2 external domain: gp75 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38992089A | 1989-08-04 | 1989-08-04 | |
US389,920 | 1989-08-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1991002062A2 WO1991002062A2 (en) | 1991-02-21 |
WO1991002062A3 true WO1991002062A3 (en) | 1991-06-13 |
Family
ID=23540312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/004340 WO1991002062A2 (en) | 1989-08-04 | 1990-08-02 | C-erbb-2 external domain: gp75 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20020155527A1 (en) |
EP (2) | EP0444181B2 (en) |
JP (2) | JP3859695B2 (en) |
AT (1) | ATE207958T1 (en) |
AU (1) | AU645760B2 (en) |
CA (1) | CA2042064C (en) |
DE (1) | DE69033842T2 (en) |
DK (1) | DK0444181T3 (en) |
ES (1) | ES2166352T3 (en) |
WO (1) | WO1991002062A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8940302B2 (en) | 2007-03-02 | 2015-01-27 | Genentech, Inc. | Predicting response to a HER inhibitor |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
DK0474727T3 (en) * | 1989-05-19 | 1998-01-12 | Genentech Inc | HER2 extracellular domain |
JP2895105B2 (en) * | 1989-09-14 | 1999-05-24 | 株式会社ニチレイ | Serodiagnosis method for breast cancer by immunoassay of c-erbB-2 oncogene product and kit therefor |
IE20000918A1 (en) | 1990-03-22 | 2001-05-30 | Sloan Kettering Inst Cancer | GP75 As a Tumor Vaccine for Melanoma |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US6953573B1 (en) | 1993-03-17 | 2005-10-11 | University Of Washington | Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated |
US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
ATE186219T1 (en) * | 1993-03-24 | 1999-11-15 | Berlex Biosciences | COMBINATION OF ANTIHORMONAL AND BINDING MOLECULES FOR CANCER TREATMENT |
IT1264083B1 (en) * | 1993-12-10 | 1996-09-10 | Enea Ente Nuove Tec | PROCEDURE FOR THE PRODUCTION IN PLANTS OF ENGINEERED ANTIBODY, PRODUCED ANTIBODY AND THEIR USE IN DIAGNOSIS AND THERAPY. |
US5783404A (en) * | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
US5759776A (en) * | 1995-06-05 | 1998-06-02 | California Pacific Medical Center | Targets for breast cancer diagnosis and treatment |
US6225054B1 (en) | 1996-01-11 | 2001-05-01 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
US6861506B1 (en) | 1996-01-11 | 2005-03-01 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
KR19990077146A (en) * | 1996-01-11 | 1999-10-25 | 길리스 스티브 | Compositions and methods for treating and diagnosing breast cancer |
US7241876B2 (en) | 1996-01-11 | 2007-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US6423496B1 (en) | 1996-01-11 | 2002-07-23 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
US6344550B1 (en) | 1996-01-11 | 2002-02-05 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
US6586570B1 (en) | 1996-01-11 | 2003-07-01 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
US6656480B2 (en) | 1996-01-11 | 2003-12-02 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
US6828431B1 (en) | 1999-04-09 | 2004-12-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US5776683A (en) * | 1996-07-11 | 1998-07-07 | California Pacific Medical Center | Methods for identifying genes amplified in cancer cells |
WO1997038085A2 (en) * | 1996-04-10 | 1997-10-16 | California Pacific Medical Center | Genes amplified in cancer cells |
US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
ATE235890T1 (en) | 1997-01-30 | 2003-04-15 | Chiron Corp | USE OF MICROPARTICLES WITH ADSORBED ANTIGEN TO STIMULATE IMMUNE DEFENSE |
ZA982968B (en) * | 1997-04-09 | 1998-10-27 | Corixa Corp | Compositions and methods for the treatment and diagnosis of breast cancer |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
US7396810B1 (en) * | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
US7198920B1 (en) | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
US6294349B1 (en) | 1999-03-01 | 2001-09-25 | University Of Mississippi Medical Ctr. | Method of diagnosing and monitoring malignant breast carcinomas |
US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
JP4579471B2 (en) * | 1999-06-25 | 2010-11-10 | ジェネンテック, インコーポレイテッド | Treatment of prostate cancer with anti-ErbB2 antibody |
AU2001259271A1 (en) * | 2000-04-28 | 2001-11-12 | Millennium Pharmaceuticals, Inc. | 14094, a novel human trypsin family member and uses thereof |
CN102698265A (en) | 2000-05-19 | 2012-10-03 | 杰南技术公司 | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
EP2305299B1 (en) | 2001-05-31 | 2017-03-01 | GlaxoSmithKline Biologicals SA | Chimeric alphavirus replicon particles |
CN100424175C (en) | 2002-03-26 | 2008-10-08 | 上海泽生科技开发有限公司 | Methods and compositions for treating neoplasms by ERBB3 |
WO2004048525A2 (en) * | 2002-11-21 | 2004-06-10 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies |
WO2005016966A2 (en) * | 2003-05-16 | 2005-02-24 | Receptor Biologix, Inc. | Intron fusion proteins, and methods of identifying and using same |
EP1745073A2 (en) * | 2004-05-14 | 2007-01-24 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
CA2571421A1 (en) | 2004-06-24 | 2006-01-05 | Nicholas Valiante | Compounds for immunopotentiation |
US20080206231A1 (en) * | 2004-10-05 | 2008-08-28 | Oregon Health And Science University | Compositions and Methods for Treating Disease |
EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
AU2006216732C1 (en) * | 2005-02-23 | 2017-07-20 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
JP2006316040A (en) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(r) adjuvant treatment |
WO2007047749A1 (en) | 2005-10-18 | 2007-04-26 | Novartis Vaccines And Diagnostics Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
WO2008154249A2 (en) * | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
WO2009003082A2 (en) * | 2007-06-26 | 2008-12-31 | Vanderbilt University | Immunological compositions as cancer biomarkers and/or therapeutics |
BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
ES2572728T3 (en) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Bispecific anti-HER antibodies |
JP5705836B2 (en) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Modulators for HER2 signaling in gastric cancer patients expressing HER2 |
JP5981853B2 (en) | 2010-02-18 | 2016-08-31 | ジェネンテック, インコーポレイテッド | Neuregulin antagonists and their use in the treatment of cancer |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
KR20130121699A (en) | 2010-05-28 | 2013-11-06 | 테트리스 온라인, 인코포레이티드 | Interactive hybrid asynchronous computer game infrastructure |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
MX2014001766A (en) | 2011-08-17 | 2014-05-01 | Genentech Inc | Neuregulin antibodies and uses thereof. |
CA2857114A1 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
JP2015514710A (en) | 2012-03-27 | 2015-05-21 | ジェネンテック, インコーポレイテッド | Diagnosis and treatment of HER3 inhibitors |
MX363188B (en) | 2012-11-30 | 2019-03-13 | Hoffmann La Roche | Identification of patients in need of pd-l1 inhibitor cotherapy. |
EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62108157A (en) * | 1985-11-06 | 1987-05-19 | Ajinomoto Co Inc | Antibody |
WO1987007646A2 (en) * | 1986-06-04 | 1987-12-17 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5169774A (en) * | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
DK0474727T3 (en) * | 1989-05-19 | 1998-01-12 | Genentech Inc | HER2 extracellular domain |
US6197855B1 (en) * | 1998-09-29 | 2001-03-06 | Solutia Inc. | Nucleation of Polyamides in the presence of hypophosphite |
-
1990
- 1990-08-02 EP EP90914094A patent/EP0444181B2/en not_active Expired - Lifetime
- 1990-08-02 EP EP99124820A patent/EP1006194A3/en not_active Withdrawn
- 1990-08-02 AU AU64135/90A patent/AU645760B2/en not_active Expired
- 1990-08-02 CA CA002042064A patent/CA2042064C/en not_active Expired - Lifetime
- 1990-08-02 ES ES90914094T patent/ES2166352T3/en not_active Expired - Lifetime
- 1990-08-02 DE DE69033842T patent/DE69033842T2/en not_active Expired - Lifetime
- 1990-08-02 WO PCT/US1990/004340 patent/WO1991002062A2/en active IP Right Grant
- 1990-08-02 JP JP51316590A patent/JP3859695B2/en not_active Expired - Fee Related
- 1990-08-02 AT AT90914094T patent/ATE207958T1/en not_active IP Right Cessation
- 1990-08-02 DK DK90914094T patent/DK0444181T3/en active
-
2001
- 2001-01-26 US US09/769,508 patent/US20020155527A1/en not_active Abandoned
-
2005
- 2005-07-07 US US11/175,405 patent/US20060019344A1/en not_active Abandoned
-
2006
- 2006-07-19 JP JP2006197085A patent/JP2006304807A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62108157A (en) * | 1985-11-06 | 1987-05-19 | Ajinomoto Co Inc | Antibody |
WO1987007646A2 (en) * | 1986-06-04 | 1987-12-17 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
Non-Patent Citations (6)
Title |
---|
"Symposia on Molecular and cellular Biology", CELL.BIOCHEM, 8 February 1990 (1990-02-08), XP002352600 * |
B.M.SEFTON: "Neus about c-erb-B-2 and HER2", TRENDS GENET, vol. 4, no. 9, September 1988 (1988-09-01), pages 247 - 248, XP002988523 * |
C.I.BARGMANN ET AL: "The neu oncogene encodes an epidermal growth factor receptor-related protein", NATURE, vol. 319, no. 6050, 16 January 1986 (1986-01-16), XP001024206 * |
CHEMICAL ABSTRACTS, vol. 107, no. 19, 1987, Columbus, Ohio, US; abstract no. 174203M, page 570; XP002988525 * |
S.KARGER (BASEL,CH), K.M. PRICE ET AL: "The production and Characterisation of monoclonal antibodies to myc, c-erbB-2 and EGF-receptor using a synthetic peptide approach", SYMPOSIUM ON MONOCLONAL ANTIBODIES FOR THERAPY, PREVENTION AND IN VIVO DIAGNOSIS OF HUMAN DISEASE, UTRECHT, 19 May 1989 (1989-05-19), UTRECHT, pages 23 - 32, XP002988526 * |
T.YAMAMOTO ET AL: "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor", NATURE, vol. 319, no. 6050, 16 January 1986 (1986-01-16), pages 230 - 234, XP002095983 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8940302B2 (en) | 2007-03-02 | 2015-01-27 | Genentech, Inc. | Predicting response to a HER inhibitor |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
Also Published As
Publication number | Publication date |
---|---|
EP1006194A2 (en) | 2000-06-07 |
DE69033842D1 (en) | 2001-12-06 |
JP3859695B2 (en) | 2006-12-20 |
WO1991002062A2 (en) | 1991-02-21 |
DE69033842T2 (en) | 2002-06-20 |
US20060019344A1 (en) | 2006-01-26 |
ES2166352T3 (en) | 2002-04-16 |
AU645760B2 (en) | 1994-01-27 |
CA2042064C (en) | 2008-10-21 |
US20020155527A1 (en) | 2002-10-24 |
EP0444181B2 (en) | 2010-11-24 |
DK0444181T3 (en) | 2002-02-25 |
ATE207958T1 (en) | 2001-11-15 |
EP0444181B1 (en) | 2001-10-31 |
JP2006304807A (en) | 2006-11-09 |
AU6413590A (en) | 1991-03-11 |
EP1006194A3 (en) | 2008-07-02 |
EP0444181A1 (en) | 1991-09-04 |
JPH04503012A (en) | 1992-06-04 |
CA2042064A1 (en) | 1991-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991002062A3 (en) | C-erbb-2 external domain: gp75 | |
CA2131826A1 (en) | MN Gene and Protein | |
WO2001055343A8 (en) | Nucleic acids, proteins, and antibodies | |
WO2002000677A8 (en) | Nucleic acids, proteins, and antibodies | |
WO1998010069A3 (en) | E25a protein, methods for production and use thereof | |
DE69126038T2 (en) | DIAGNOSIS OF CANCER METASTASES BY THE MTS-1 GEN | |
EP0833948A4 (en) | Colon specific gene and protein | |
PT1299727E (en) | Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers | |
WO2001055300A8 (en) | Nucleic acids, proteins, and antibodies | |
EP1243653A3 (en) | E25a protein, methods for producing and use thereof | |
WO2001055313A3 (en) | Nucleic acids, proteins, and antibodies | |
WO2001055329A3 (en) | Nucleic acids, proteins, and antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2042064 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990914094 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWP | Wipo information: published in national office |
Ref document number: 1990914094 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1990914094 Country of ref document: EP |